Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EPCORITAMAB-BYSP for B-cell lymphoma refractory: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 15 adverse event reports in the FDA FAERS database where EPCORITAMAB-BYSP was used for B-cell lymphoma refractory.

Most Reported Side Effects for EPCORITAMAB-BYSP

Side Effect Reports % Deaths Hosp.
Cytokine release syndrome 369 37.7% 136 87
Diffuse large b-cell lymphoma 206 21.1% 112 25
Diffuse large b-cell lymphoma refractory 198 20.3% 101 25
Pyrexia 79 8.1% 29 26
Immune effector cell-associated neurotoxicity syndrome 77 7.9% 34 28
Covid-19 39 4.0% 18 18
Neutrophil count decreased 35 3.6% 11 12
Hypogammaglobulinaemia 32 3.3% 7 8
Platelet count decreased 32 3.3% 11 11
Cytomegalovirus infection 31 3.2% 10 12
Pneumonia 29 3.0% 16 13
Cytomegalovirus infection reactivation 26 2.7% 7 5
Death 25 2.6% 25 4
Malignant neoplasm progression 24 2.5% 10 1
Hypoalbuminaemia 20 2.0% 8 4

Other Indications for EPCORITAMAB-BYSP

Diffuse large b-cell lymphoma (362) Diffuse large b-cell lymphoma refractory (353) Product used for unknown indication (64) Diffuse large b-cell lymphoma recurrent (26) Follicular lymphoma (19) B-cell lymphoma (16) Follicular lymphoma refractory (12) High-grade b-cell lymphoma (10) Lymphoma (7)

Other Drugs Used for B-cell lymphoma refractory

RITUXIMAB (103) OBINUTUZUMAB (84) CISPLATIN (53) ETOPOSIDE (49) DEXAMETHASONE (45) AXICABTAGENE CILOLEUCEL (44) CYCLOPHOSPHAMIDE (43) CYTARABINE (40) IBRUTINIB (39) LENALIDOMIDE (36)

Related Pages

EPCORITAMAB-BYSP Full Profile All B-cell lymphoma refractory Drugs EPCORITAMAB-BYSP Demographics EPCORITAMAB-BYSP Timeline